ConductScience.org, home

Paper37768367

Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.

Jesus MM and 20 others. Parasitol Res, 2023. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis. Papers, record 37768367. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37768367

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Immunization with recombinant LiHyp1 protein plus adjuvant is protective against tegumentary leishmaniasis.
PubMed
Journal
Parasitol Res
PubMed
Year
2023
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2026-10-31
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Jesus MMMarcelo M
2Lage DPDaniela P
3Vale DLDanniele L
4Freitas CSCamila S
5Pimenta BLBreno L
6Moreira GJLGabriel J L
7Ramos FFFernanda F
8Pereira IAGIsabela A G
9Bandeira RSRaquel S
10Ludolf FFernanda
11Tavares GSVGrasiele S V
12Galdino ASAlexsandro S
13Duarte MCMariana C
14Menezes-Souza DDaniel
15Chávez-Fumagalli MAMiguel A
16Teixeira ALAntônio L
17Gonçalves DUDenise U
18Roatt BMBruno M
19Christodoulides MMyron
20Martins VTVívian T

Source PubMed

See all 21 authorsDownload CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
LeishmaniasisMajor topic
Leishmaniasis, VisceralMajor topic
Leishmania infantumMajor topic
SaponinsMajor topic
Humans
Animals
Mice
Micelles
Leukocytes, Mononuclear
Recombinant Proteins
Adjuvants, Immunologic
Cytokines
Vaccination
Mice, Inbred BALB C
Antigens, Protozoan

Source PubMed

Download CSV of topics

References52

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112819086Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.Infect Immun2003https://conductscience.org/library/papers/12819086PubMed
231155395Diagnostic evaluation of the amastin protein from Leishmania infantum in canine and human visceral leishmaniasis and immunogenicity in human cells derived from patients and healthy controls.Diagn Microbiol Infect Dis2019https://conductscience.org/library/papers/31155395PubMed
332949849Leishmania infantum transfected with toxic plasmid induces protection in mice infected with wild type L. infantum or L. amazonensis.Mol Immunol2020https://conductscience.org/library/papers/32949849PubMed
48358705Leishmaniases of the New World: current concepts and implications for future research.Clin Microbiol Rev1993https://conductscience.org/library/papers/8358705PubMed
532485231Biotechnological applications from a Leishmania amastigote-specific hypothetical protein in the canine and human visceral leishmaniasis.Microb Pathog2020https://conductscience.org/library/papers/32485231PubMed
629240765Drug resistance and treatment failure in leishmaniasis: A 21st century challenge.PLoS Negl Trop Dis2017https://conductscience.org/library/papers/29240765PubMed
729922885Molecular Diagnosis of Visceral Leishmaniasis.Mol Diagn Ther2018https://conductscience.org/library/papers/29922885PubMed
836986434Recent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections.Pharmaceuticals (Basel)2023https://conductscience.org/library/papers/36986434PubMed
932656269Review on the Role of Host Immune Response in Protection and Immunopathogenesis during Cutaneous Leishmaniasis Infection.J Immunol Res2020https://conductscience.org/library/papers/32656269PubMed
1018295939Vaccines for leishmaniasis in the fore coming 25 years.Vaccine2008https://conductscience.org/library/papers/18295939PubMed
1134511000From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection.Expert Rev Vaccines2021https://conductscience.org/library/papers/34511000PubMed
1232972825A historical review of the role of cytokines involved in leishmaniasis.Cytokine2021https://conductscience.org/library/papers/32972825PubMed
1322272364Identification of proteins in promastigote and amastigote-like Leishmania using an immunoproteomic approach.PLoS Negl Trop Dis2012https://conductscience.org/library/papers/22272364PubMed
1426872697Interleukin-35 Limits Anti-Tumor Immunity.Immunity2016https://conductscience.org/library/papers/26872697PubMed
1533825036Leishmaniasis: where are we and where are we heading?Parasitol Res2021https://conductscience.org/library/papers/33825036PubMed
1635437797Leishmania LiHyC protein is immunogenic and induces protection against visceral leishmaniasis.Parasite Immunol2022https://conductscience.org/library/papers/35437797PubMed
1732526867Liposomal Formulation of ChimeraT, a Multiple T-Cell Epitope-Containing Recombinant Protein, Is a Candidate Vaccine for Human Visceral Leishmaniasis.Vaccines (Basel)2020https://conductscience.org/library/papers/32526867PubMed
1816305646Immune response in human visceral leishmaniasis: analysis of the correlation between innate immunity cytokine profile and disease outcome.Scand J Immunol2005https://conductscience.org/library/papers/16305646PubMed
192063957Leishmaniasis in Bahia, Brazil: evidence that Leishmania amazonensis produces a wide spectrum of clinical disease.Am J Trop Med Hyg1991https://conductscience.org/library/papers/2063957PubMed
2025476593IL-35: a potential therapeutic target for controlling hepatitis B virus infection.J Dig Dis2015https://conductscience.org/library/papers/25476593PubMed

See all 52 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
40900277
Leishmania pyruvate kinase and mitochondrial processing protease: Two novel vaccine candidates, selected via a seroproteomic approach, trigger a protective immune response against murine cutaneous leishmaniasis.
Med Microbiol Immunol2025https://conductscience.org/library/papers/40900277

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37768367

GET https://conductscience.org/api/papers/v1/37768367/authors?page=2